Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
about
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
description
article
@en
im Juni 2018 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2018
@uk
ലേഖനം
@ml
name
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@en
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@nl
type
label
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@en
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@nl
prefLabel
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@en
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@nl
P2093
P2860
P50
P921
P1476
Antimalarial activity of singl ...... pt, open-label, phase 2a study
@en
P2093
Annie N Cowell
Caroline L Ng
Elizabeth A Winzeler
Felix D Rozenberg
Juan-Carlos Hinojosa
Jörg J Möhrle
Margaret A Phillips
Maria Rosario
Mark Baker
P2860
P304
P356
10.1016/S1473-3099(18)30309-8
P407
P577
2018-06-13T00:00:00Z